Holen Sie sich die Stockscreener-App
2.61
2.76%
0.07
Schlusskurs vom Vortag:
$2.54
Offen:
$2.64
24-Stunden-Volumen:
16,946
Relative Volume:
0.01
Marktkapitalisierung:
$6.47M
Einnahmen:
$556.00K
Nettoeinkommen (Verlust:
$-5.28M
KGV:
-1.2196
EPS:
-2.14
Netto-Cashflow:
$-6.23M
1W Leistung:
+1.56%
1M Leistung:
-2.25%
6M Leistung:
+3.98%
1J Leistung:
-17.41%
1-Tages-Spanne:
$2.50
$2.68
1-Wochen-Bereich:
$2.4377
$2.8505
52-Wochen-Spanne:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Firmenname
Cyclerion Therapeutics Inc
Sektor
Branche
Telefon
617-621-7722
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie CYCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.61 | 6.47M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-20 | Eingeleitet | Truist | Buy |
| 2021-09-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-03 | Eingeleitet | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Aktie (CYCN) Neueste Nachrichten
Dementia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
Top Gainers Today: Reborn Coffee (REBN) Leads with a 65% Surge, Cyclerion (CYCN) and Signing Day Sports (SGN) Follow – market - HPBL
3 US Penny Stocks With Market Caps Over $10M To Consider - Simply Wall St
Cyclerion Therapeutics Inc (NASDAQ: CYCN) Is The Number One Stock Currently Moving. - Stocks Register
Market Recap Check: Cyclerion Therapeutics Inc (CYCN)’s Negative Finish at 4.19, Up/Down -21.24 - The Dwinnex
Small Cap Stocks To ConsiderFebruary 02nd - MarketBeat
Cyclerion Therapeutics announces mixed shelf offering - MSN
Cyclerion Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Check out these key findings about Cyclerion Therapeutics Inc (CYCN) - SETE News
3 Penny Stocks to Watch Now, 2/4/25 - TipRanks
A company insider recently sold 357,880 shares of Cyclerion Therapeutics Inc [CYCN]. Should You also Consider to Sale? – Knox Daily - Knox Daily
Analyzing CYCN’s current quarter earnings projections - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Stock market today: Signing Day Sports +62.89%, Cyclerion Therapeutics +57.43% among top gainers in early trading - Business Upturn
Top Premarket Gainers -January 31, 2025 at 07:32 am EST - Marketscreener.com
Stock market today: Perfect Moment posted rise of 89.86% whereas Enveric Biosciences saw fall of 45.64% in early trading - Business Upturn
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 3.5% – Time to Buy? - Defense World
Looking Into Cyclerion Therapeutics's Recent Short Interest - Benzinga
Extended Session Gains Propel Cyclerion (CYCN) Amid Revenue Progress - Stocks Telegraph
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion advances growth strategy with new agreements By Investing.com - Investing.com UK
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Finanzdaten der Cyclerion Therapeutics Inc-Aktie (CYCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):